Purple Biotech Stock Price To Earning

PPBT Stock

USD 2.74 0.55 25.11%

Purple Biotech fundamentals help investors to digest information that contributes to Purple Biotech's financial success or failures. It also enables traders to predict the movement of Purple Stock. The fundamental analysis module provides a way to measure Purple Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Purple Biotech stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Purple Biotech Company Price To Earning Analysis

Purple Biotech's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Purple Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Purple Biotech is extremely important. It helps to project a fair market value of Purple Stock properly, considering its historical fundamentals such as Price To Earning. Since Purple Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Purple Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Purple Biotech's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Net Tangible Assets	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Short Term Debt	Intangible Assets	Good Will
Total Assets		1.0	-0.76	-0.77	0.57	0.28	0.58	0.97	0.89	0.77	0.96	0.76	0.97	0.92	-0.75	0.7	-0.18
Total Stockholder Equity	1.0		-0.73	-0.73	0.53	0.24	0.52	0.99	0.91	0.81	0.95	0.72	0.98	0.94	-0.73	0.73	-0.15
Net Debt	-0.76	-0.73		0.88	-0.82	-0.26	-0.78	-0.69	-0.56	-0.27	-0.75	-0.66	-0.68	-0.48	0.69	-0.27	0.51
Retained Earnings	-0.77	-0.73	0.88		-0.94	-0.43	-0.95	-0.64	-0.56	-0.21	-0.83	-0.79	-0.73	-0.48	0.83	-0.21	0.64
Accounts Payable	0.57	0.53	-0.82	-0.94		0.38	0.93	0.43	0.43	-0.01	0.69	0.68	0.56	0.25	-0.74	-0.07	-0.82
Net Receivables	0.28	0.24	-0.26	-0.43	0.38		0.45	0.21	-0.07	-0.09	0.29	0.65	0.18	0.12	-0.66	0.04	-0.12
Total Liab	0.58	0.52	-0.78	-0.95	0.93	0.45		0.43	0.34	-0.05	0.66	0.66	0.54	0.25	-0.71	-0.03	-0.75
Total Current Assets	0.97	0.99	-0.69	-0.64	0.43	0.21	0.43		0.89	0.85	0.89	0.65	0.96	0.96	-0.66	0.77	-0.08
Net Tangible Assets	0.89	0.91	-0.56	-0.56	0.43	-0.07	0.34	0.89		0.86	0.89	0.52	0.94	0.91	-0.52	0.64	-0.17
Short Term Investments	0.77	0.81	-0.27	-0.21	-0.01	-0.09	-0.05	0.85	0.86		0.68	0.34	0.81	0.95	-0.32	0.87	0.29
Property Plant Equipment	0.96	0.95	-0.75	-0.83	0.69	0.29	0.66	0.89	0.89	0.68		0.8	0.95	0.85	-0.79	0.59	-0.29
Current Deferred Revenue	0.76	0.72	-0.66	-0.79	0.68	0.65	0.66	0.65	0.52	0.34	0.8		0.69	0.58	-0.98	0.39	-0.24
Net Invested Capital	0.97	0.98	-0.68	-0.73	0.56	0.18	0.54	0.96	0.94	0.81	0.95	0.69		0.94	-0.71	0.69	-0.24
Net Working Capital	0.92	0.94	-0.48	-0.48	0.25	0.12	0.25	0.96	0.91	0.95	0.85	0.58	0.94		-0.57	0.86	0.09
Short Term Debt	-0.75	-0.73	0.69	0.83	-0.74	-0.66	-0.71	-0.66	-0.52	-0.32	-0.79	-0.98	-0.71	-0.57		-0.36	0.35
Intangible Assets	0.7	0.73	-0.27	-0.21	-0.07	0.04	-0.03	0.77	0.64	0.87	0.59	0.39	0.69	0.86	-0.36		0.47
Good Will	-0.18	-0.15	0.51	0.64	-0.82	-0.12	-0.75	-0.08	-0.17	0.29	-0.29	-0.24	-0.24	0.09	0.35	0.47

Click cells to compare fundamentals

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Competition

Predict Purple Biotech

Purple Retained Earnings

Retained Earnings

(130.58 Million)

At this time, Purple Biotech's Retained Earnings are comparatively stable compared to the past year.

Based on the latest financial disclosure, Purple Biotech has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.

Purple Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Purple Biotech's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Purple Biotech could also be used in its relative valuation, which is a method of valuing Purple Biotech by comparing valuation metrics of similar companies.

Purple Biotech is currently under evaluation in price to earning category among its peers.

Purple Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Purple Biotech from analyzing Purple Biotech's financial statements. These drivers represent accounts that assess Purple Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Purple Biotech's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	14.3M	44.8M	67.6M	26.2M	20.2M	16.9M
Enterprise Value	10.1M	34.5M	57.4M	11.7M	6.1M	11.0M

Purple Biotech ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Purple Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Purple Biotech's managers, analysts, and investors.

Environmental

Governance

Social

Purple Fundamentals

	Return On Equity	-0.45
	Return On Asset	-0.29
	Current Valuation	(1.95 M)
	Shares Outstanding	1.57 M
	Shares Owned By Insiders	2.86 %
	Shares Owned By Institutions	9.33 %
	Number Of Shares Shorted	19.52 K
	Price To Book	0.12 X
	Price To Sales	58.08 X
	Gross Profit	(120 K)
	EBITDA	(22.23 M)
	Net Income	(19.88 M)
	Cash And Equivalents	36.02 M
	Cash Per Share	2.00 X
	Total Debt	351 K
	Debt To Equity	0.01 %
	Current Ratio	6.94 X
	Book Value Per Share	0.14 X
	Cash Flow From Operations	(19.23 M)
	Short Ratio	0.43 X
	Earnings Per Share	81.00 X
	Target Price	33.0
	Number Of Employees	20
	Beta	0.38
	Market Capitalization	3.43 M
	Total Asset	44.3 M
	Retained Earnings	(137.45 M)
	Working Capital	8.61 M
	Net Asset	44.3 M

About Purple Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Purple Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Purple Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Purple Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Purple Stock Analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC